← All trials
NCT05666219
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 19, 2022
- Primary completion
- Jun 18, 2023
- Completion date
- Jun 18, 2023
- First posted
- Dec 26, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 73
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of PakistanLead sponsor
- Government of PakistanStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.